The China lung cancer screening market has witnessed substantial growth over the past decade, driven by rising lung cancer prevalence and increasing government initiatives focused on early detection. Lung cancer remains one of the deadliest cancers in China, claiming over 700,000 lives annually. Despite advancements in treatment modalities, most diagnoses occur at late stages when curative therapies are less effective. Consequently, screening programs, particularly using Low-Dose Computed Tomography (LDCT), have emerged as a crucial strategy to improve early detection rates and enhance patient survival outcomes. LDCT offers high sensitivity for early-stage lung cancer, enabling timely medical intervention that significantly reduces mortality.
The market size of China’s lung cancer screening sector is projected to reach US$ 1,295.5 million by 2032, up from US$ 616.2 million in 2025, reflecting a compound annual growth rate (CAGR) of 11.2% over the forecast period. This growth is supported by government-backed programs, rising adoption of LDCT, and technological innovations such as artificial intelligence (AI)-assisted diagnostics. Among screening modalities, LDCT is expected to maintain a dominant market share of approximately 71.4% in 2025, while provinces such as Shandong emerge as key geographical hubs due to their proactive screening initiatives and high disease burden. These trends indicate a robust trajectory for the market, shaped by strategic public health policies, increasing health awareness, and ongoing technological advancements.
Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/35427
Key Highlights from the Report
• Government-backed LDCT programs and rising lung cancer burden accelerate early detection efforts in China.
• Collaborations between AI firms and hospital systems are improving screening accuracy and reducing radiologist workload.
• LDCT scan is expected to hold around 71.4% share in 2025 due to superior early-stage detection capabilities.
• Shandong province is witnessing steady growth amid strong uptake of opportunistic LDCT screening.
• Non-Small Cell Lung Cancer (NSCLC) remains the dominant cancer type due to rising adenocarcinoma incidence.
• Provincial disparities in access create opportunities for mobile CT solutions and tele-radiology platforms.
Market Segmentation
The China lung cancer screening market can be segmented based on cancer type, diagnostic technology, and end-users. By cancer type, the market is divided into Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). NSCLC dominates the market, projected to account for 82.4% share by 2025, owing to the high incidence of adenocarcinoma and squamous cell carcinoma in the Chinese population. These tumors often present as peripheral lesions or ground-glass nodules, which are more readily detected by LDCT. SCLC, though less common, is expected to register moderate growth due to increasing smoking prevalence in specific provinces such as Hebei.
In terms of diagnostic modalities, the market primarily includes LDCT scans and chest X-rays (CXR). LDCT leads due to its high sensitivity, accessibility, and cost-effectiveness. Programs under China’s National Lung Cancer Screening (NLCS) have improved uptake by offering transport assistance, awareness campaigns, and streamlined screening processes. Chest X-rays, while less sensitive than LDCT, remain relevant as a preliminary screening tool, especially in community health settings. They enhance public familiarity with lung cancer screening and serve as a benchmark for newer technologies.
End-user segmentation includes hospitals, diagnostic centers, and government programs. Hospitals and diagnostic centers represent the largest end-user group, driven by increasing investments in imaging infrastructure and skilled radiology personnel. Government programs also contribute significantly, as public insurance initiatives and provincial screening campaigns expand access to high-risk populations.
Regional Insights
Regional trends indicate that certain provinces are at the forefront of lung cancer screening adoption in China. Shandong province has a high lung cancer burden, with age-standardized incidence and mortality rates exceeding national averages. The province has integrated LDCT screening into its public health framework, particularly targeting high-risk populations aged 50–75 with a history of smoking or exposure to environmental pollutants.
Sichuan province exhibits strong urban screening coverage, with over 95% of high-risk individuals able to reach LDCT facilities within 60 minutes. However, rural and ethnic minority areas show spatial inequities in access, highlighting the need for mobile CT units and tele-radiology solutions. Jiangsu province, as a developed region, consistently demonstrates higher LDCT uptake due to better healthcare infrastructure, media outreach, and streamlined follow-up pathways. These regional dynamics emphasize the role of infrastructure, awareness campaigns, and targeted interventions in shaping the market landscape.
Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/35427
Market Drivers
The China lung cancer screening market is primarily driven by government-backed initiatives aimed at early detection. Programs like the National Cancer Screening Program (NCSP) and the National Lung Cancer Screening (NLCS) initiative provide funding, guidelines, and technical support for LDCT-based screening. Policymakers have emphasized China-specific evidence, including demographic trends, non-smoking-related adenocarcinoma prevalence, and aging patterns, which strengthens acceptance among healthcare providers and insurers.
Rising lung cancer incidence and mortality rates also act as major growth drivers. With over 820,000 new cases reported in 2020, the disease remains a top public health priority. Increased awareness among the population, combined with advancements in imaging technologies and AI-assisted diagnostics, further enhances screening uptake. AI systems, now deployed across multiple hospitals, improve nodule detection accuracy and reduce radiologist workload, addressing previous bottlenecks in early diagnosis.
Market Restraints
Despite growth potential, the China lung cancer screening market faces challenges that may hinder its expansion. Low uptake of screening programs remains a key issue. Studies in Henan province reveal that less than 50% of high-risk individuals invited for LDCT screening actually completed the procedure. Contributing factors include logistical barriers, out-of-pocket follow-up costs, low health literacy, and workplace constraints.
High false-positive rates further complicate the scenario, leading to unnecessary follow-up imaging, biopsies, and patient anxiety. For instance, a nationwide cohort study reported a false-positive rate of nearly 69%, with only a small fraction of flagged nodules confirmed as malignant. This diagnostic uncertainty discourages participation and strains healthcare resources, limiting the overall effectiveness of early detection programs.
Market Opportunities
Significant opportunities exist in the integration of AI and advanced imaging analytics within lung cancer screening programs. AI-assisted LDCT has demonstrated accuracy rates exceeding 90% in nodule detection and Lung-RADS risk categorization. Such technological advancements not only improve diagnostic precision but also reduce the burden on radiologists, allowing for larger-scale implementation of screening programs.
Moreover, China-specific guidelines targeting younger, non-smoking women exposed to indoor pollutants open new market segments. Early detection of adenocarcinomas in these populations enhances survival outcomes and highlights the potential for preventive strategies tailored to regional demographics. Mobile CT solutions and tele-radiology platforms further present opportunities to address spatial inequities and expand screening access in rural and underserved regions.
Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/35427
Company Insights
Several domestic and international companies are leading the China lung cancer screening market by providing advanced imaging solutions and LDCT technologies. Key players include:
• Biodesix
• GE HealthCare
• DELFI Diagnostics, Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• CANON MEDICAL SYSTEMS CORPORATION
• Siemens Healthineers AG
• Medtronic plc
• Koninklijke Philips N.V.
• Freenome Holdings, Inc.
• Shanghai United Imaging Healthcare Co., LTD
Recent Developments:
In April 2025, researchers at the Guangzhou Institute of Respiratory Disease found that LDCT screening detected lung cancer in non-smokers at rates comparable to smokers, reinforcing its value across demographic segments.
In January 2025, a study conducted at Sichuan University revealed that only 23.88% of urban residents reported adequate awareness of lung cancer, underscoring the need for public education campaigns to boost screening participation.
Conclusion
The China lung cancer screening market is on a strong growth trajectory, underpinned by government support, rising lung cancer incidence, and technological advancements such as AI-assisted diagnostics. LDCT remains the leading screening modality, while NSCLC dominates the cancer-type segment due to the prevalence of adenocarcinoma. Regional trends show higher uptake in provinces with advanced infrastructure and proactive public health programs, such as Shandong, Sichuan, and Jiangsu.
Despite challenges such as low participation rates and high false-positive findings, opportunities abound in AI integration, mobile screening solutions, and targeted interventions for non-smoking high-risk populations. Leading market players continue to innovate, enhancing early detection and optimizing patient outcomes. With continued policy support and technological evolution, the China lung cancer screening market is poised to significantly reduce mortality and transform public health outcomes across the nation.
